Akari Therapeutics is a revolutionary brand that specializes in developing life-transforming treatments for autoinflammatory and orphan diseases. They focus on targeting the complement (C5) and leukotriene (LTB4) pathways, offering innovative solutions for patients battling these conditions. Their pipeline consists of groundbreaking treatments such as HSCT-TMA and Nomacopan, which have shown great promise in addressing autoinflammatory diseases.

Additionally, they have made significant progress in developing treatments for Geographic Atrophy (GA). Akari Therapeutics is dedicated to improving the lives of patients and has recently established a Boston U. S.

They are also conducting Phase 3 clinical trials, further demonstrating their commitment to delivering effective treatments. With the recent appointment of Beth-Anne Lang as Senior Vice President of Regulatory Affairs, the brand continues to prioritize excellence and expertise in their team. As a leader in the field, Akari Therapeutics has been recognized for their contributions, receiving the Nomacopan Orphan Drug Designation from the European Commission.

With an experienced executive team and a continuous drive for innovation, Akari Therapeutics is at the forefront of revolutionizing the treatment of autoinflammatory and orphan diseases